Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences
19 avr. 2022 08h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...
Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022
08 avr. 2022 13h02 HE
|
Kymera Therapeutics, Inc.
MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition in p53 wild-type tumors and led to tumor regressions in xenograft...
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
02 mars 2022 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
24 févr. 2022 07h00 HE
|
Kymera Therapeutics, Inc.
Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines...
Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences
25 janv. 2022 08h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors
18 janv. 2022 08h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company
10 janv. 2022 07h00 HE
|
Kymera Therapeutics, Inc.
Company plans to establish Proof-of-Mechanism and -Biology in patients in immune-inflammatory and oncology indications across its three ongoing clinical programs: IRAK4, IRAKIMiD and STAT3 KT-474...
Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
04 janv. 2022 08h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day
16 déc. 2021 07h00 HE
|
Kymera Therapeutics, Inc.
Multiple Ascending Dose (MAD) data from KT-474 Phase 1 trial demonstrates near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines, and...
Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting
13 déc. 2021 08h00 HE
|
Kymera Therapeutics, Inc.
Two presentations demonstrated Kymera’s STAT3 degraders can reduce STAT3 expression, modify STAT3-dependent signaling, and suppress the growth of tumors in multiple preclinical models of lymphoma and...